SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Creative Media & Community Trust Corp. is a real estate investment trust that seeks to own, operate, and develop premier multifamily and creative office assets in vibrant and emerging communities throughout the United States. It operates through the following segments: Office, Hotel, and Lending. The Office segment consists of the rental of office space and other tenant services, including tenant reimbursements, parking, and storage space rental. The Hotel segment involves the operation of hotel properties. The Lending segment focuses on loans to small businesses. The company was founded in 1993 and is headquartered in Dallas, TX.

Creative Media & Community Trust

CMCT is trending due to significant momentum and volume, leading to a breakout and potential short squeeze. Community members are actively discussing profit-taking strategies, with some suggesting the stock could become the next low-float runner. The stock's low float and potential for a squeeze are major talking points.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversations around DJT are heavily focused on political affiliations following a shooting involving Charlie Kirk, with community members debating the shooter's motives and ideological alignment. Some users are pointing fingers between the left and right, while others are highlighting the broader implications of political rhetoric and violence. The stock is also being discussed in relation to broader market trends and potential financial impacts.

Asset Entities, Inc. engages in providing social media marketing and content delivery services. It offers its services to Discord, TikTok, and other social media platforms. It also designs, develops and manages servers for communities on Discord. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani and Kyle Fairbanks on August 1, 2020 and is headquartered in Dallas, TX.

Asset Entities Inc - Ordinary Shares - Class B

Asset Entities Inc.

Asset Entities is trending as the community anticipates a potential short squeeze following the completion of its merger with Strive Enterprises; traders are closely watching for a CUSIP change and its potential impact on short positions. Chatter revolves around the possibility of the company investing its substantial treasury into Bitcoin, drawing comparisons to other companies in the crypto space. Some traders express frustration that the price has not yet reflected the merger news and the potential for a short squeeze.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP.X is trending as the community speculates on potential catalysts, including a possible spot ETF and upcoming rate cuts, while also closely monitoring price action and key resistance levels. Discussions include both bullish sentiment, with some anticipating a significant breakout, and skepticism regarding its performance compared to other cryptocurrencies. Traders are actively debating strategies around accumulating and holding versus taking profits.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

ATYR is trending as traders anticipate Phase 3 data, expected mid-September, with the community actively debating potential outcomes and price targets. Bullish sentiment is fueled by recent institutional buying and analyst ratings, while bears cite concerns over trial design and past performance, with some highlighting the involvement of controversial figures known for short selling. The potential for a short squeeze and the high implied volatility are adding to the speculative buzz.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Gemini Space Station ($GEMI) is trending after its IPO, with the community actively discussing its potential and comparing it to other recent IPOs. Some investors are excited about the company's prospects and credit card rewards program, while others express concerns about its valuation and potential for a pullback. The stock's initial trading volatility and comparison to other crypto-related companies are also key talking points.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending due to a recently announced $20 million investment agreement, sparking significant price movement and active discussion about its potential. The community is focused on the stock's low float and speculating about a potential short squeeze, while also keeping an eye on an upcoming investor summit. Some traders are also wary of dilution and high volatility.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

$BROKE.X is trending due to the excitement surrounding its upcoming listing on BiFinance and a live 'Biggest Buy Contest', which the community sees as key catalysts. The community emphasizes that the project is built on organic growth and hard work, not hype, and they are rallying together to push the coin to new all-time highs. Many community members express strong conviction and encourage others to DYOR and join their Telegram group to learn more.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending downwards as reports circulate that the Trump administration may link COVID-19 vaccines to child deaths, creating uncertainty around the stock's future. The community is discussing the potential impact of this news, while some investors see a buying opportunity due to the perceived overreaction and low valuation. Discussions also include Moderna's pipeline beyond COVID-19, especially its personalized cancer vaccine program.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amid discussions around the implications of potential shifts in government policy regarding COVID-19 vaccines, including concerns about linking vaccines to child deaths. The community is weighing the potential impact on Pfizer's revenue and future prospects, with some questioning liability and others pointing to the company's broader pipeline beyond vaccines. Additionally, some traders are closely monitoring technical indicators and dividend payouts, viewing the dip as a possible buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Chewy (CHWY) Is a Good Investment: Is It?

The average brokerage recommendation (ABR) for Chewy (CHWY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Chewy Q2 Earnings Beat Estimates, FY25 Sales Outlook Raised

CHWY posts strong second-quarter results with rising Autoship sales and higher margins. It raises the full-year sales outlook.

JPMorgan on Wednesday maintained its 'Overweight' rating on Chewy stock, calling the over 16% drop following the company's quarterly results an overreaction, according to the summary of the investor note on The Fly.Chewy reported second-quarter revenue above expectations and adjusted earnings per share (EPS) in line with targets. The company boosted its full-year sales forecast to a $12.5 billion to $12.6 billion range, up from $12.3 billion to $12.45 billion.However, a 79% fall in quarterly net profit and less-than-expected investment into the business&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/chewy-stock-sinks-15-as-q2-net-income-falls/chwkSi4RduH">raised concerns</a>, causing the shares to fall.JP Morgan, which trimmed its price target on the company's shares by $2 to $45, noted that investors are likely worried about margin compression in the second half of the year.The slide also follows recent momentum in the stock. Before Wednesday's session, CHWY shares had gained nearly 23% since a recent low in August, and 27% year-to-date.Currently, 18 of the 28 analysts covering the stock rate it 'buy' or higher, and nine rate it 'hold,' according to Koyfin data. Their average price target is $45.6, implying a 30% upside from the last close.Stocktwits users noted the drop to be a buying opportunity, with retail sentiment climbing higher in the 'extremely bullish' zone.<stembedurl>https://stocktwits.com/JOEYBUYDEN/message/628242827</stembedurl>Analysts have previously raised concerns about the company’s<a href="https://stocktwits.com/news-articles/markets/equity/chewy-analyst-steps-to-sidelines-on-valuation-concerns-retail-agrees/chkzXthRbx0">&nbsp;high valuation</a> (Chewy stock hit a two-and-a-half-year high in June).&nbsp;Still,&nbsp;its financials have improved in recent quarters, driven by wider adoption of its Autoship subscription program,&nbsp;which lets customers schedule deliveries and gain priority access to popular products and essentials.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ai-upstart-perplexity-hits-whopping-20b-valuation-with-new-200m-raise-report/chwNEBCRdHQ">AI Upstart Perplexity Hits Whopping $20B Valuation With New $200M Raise: Report</a>

A woman opening online parcels with her dog. (Photo: Edwin Tan via Getty Images)

Chewy Retail Watchers Sniff Buying Opportunity After 16% Plunge Post Earnings — Analyst Calls Selloff Overblown

Investment advisory firms JP Morgan and Mizuho maintained their 'buy' calls post the pet product retailer's second quarter report.

Equity

Investment advisory firms JP Morgan and Mizuho maintained their 'buy' calls post the pet product retailer's second quarter report.


Chewy Inc (CHWY) shares tumbled 15% during midday trading on Wednesday after the company posted a fall in second-quarter (Q2) net income due to higher operating expenses.The company’s quarterly net income fell to $62 million, compared to $299.1 million a year ago. Operating expenses in the quarter rose 7.5% to $872.5 million.Retail sentiment on <a href="https://stocktwits.com/symbol/CHWY">Chewy</a> remained unchanged in the ‘extremely bullish’ territory, with chatter at ‘extremely high’ levels, according to data from Stocktwits.<figure class="image"><img style="aspect-ratio:807/105;" src="https://news.stocktwits-cdn.com/CHWY_sentiment_png_09dd7d62a3.webp" alt="CHWY sentiment.png" width="807" height="105"><figcaption>CHWY sentiment and message volume September 10, 2025, as of 12 pm ET | Source: Stocktwits</figcaption></figure>Analysts at Mizuho noted that Chewy shares are down meaningfully on "another OpEx miss" and incremental investments planned for the second half, according to TheFly.The firm said that even though it acknowledges that re-investing upside is "disappointing," it thinks this could expedite revenue upside and believes shares being off by more than 15% "seems like too much."Mizuho also added that Q2 results came in slightly ahead of expectations. The firm maintained its ‘Outperform’ rating and $50 price target on Chewy.Chewy’s Q2 revenue came in at $3.10 billion, edging past Wall Street expectations of $3.08 billion, according to data compiled by Fiscal AI. Its adjusted earnings per share (EPS) of $0.33 came in line with analysts’ estimates.Separately, the company also announced the launch of “Get Real,” a new line of minimally processed, fresh dog food available only at Chewy as part of its efforts to build on the growing demand for pet food.Shares of Chewy have gained 4% this year and have jumped over 15% in the last 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-wlds-stock-skyrocket-850-today/chwkKHrRdus">Why Did WLDS Stock Skyrocket 850% Today?</a>

Chewy stock had made headlines recently after Keith Gill a.k.a ‘Roaring Kitty’ disclosed a stake in the firm.

Chewy Stock Sinks 15% As Q2 Net Income Falls: Here's What This Analyst Has To Say

Analysts at Mizuho noted that Chewy shares are down meaningfully on "another OpEx miss" and incremental investments planned for the second half.

Chewy (CHWY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Chewy (CHWY) give a sense of how the business performed in the quarter ended July 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Chewy (CHWY) Meets Q2 Earnings Estimates

Chewy (CHWY) delivered earnings and revenue surprises of 0.00% and +0.71%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

Chewy (CHWY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Beyond analysts' top-and-bottom-line estimates for Chewy (CHWY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended July 2025.

Chewy (CHWY) Suffers a Larger Drop Than the General Market: Key Insights

Chewy (CHWY) concluded the recent trading session at $39.44, signifying a -3.71% move from its prior day's close.

Chewy (CHWY) Is Considered a Good Investment by Brokers: Is That True?

According to the average brokerage recommendation (ABR), one should invest in Chewy (CHWY). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Why Chewy (CHWY) Outpaced the Stock Market Today

The latest trading day saw Chewy (CHWY) settling at $40.75, representing a +2.53% change from its previous close.

Chewy, Inc. operates as an online retailer of pet food and other pet-related products and services. It supplies pet medications, food, treats and other pet-health products and services for dogs, cats, fish, birds, small pets, horses, and reptiles. It has a portfolio of pet healthcare offerings that includes Chewy Pharmacy, Connect with a Vet, and CarePlus, an exclusive suite of pet-first insurance and wellness plans. The company was founded by Ryan Cohen and Michael Day in September 2011 and is headquartered in Plantation, FL.

Current Price	$34.66
Prev Close	$36.02
Open	$35.62
Dividend Yield	0.00%
50-Day Moving Average	$38.60
Beta	1.42
Avg. Volume	6.22M
PE Ratio	101.64

52-Week High	$48.62
52-Week Low	$26.28
Market Capitalization	$15B
EPS (Annual)	$0.9112
Price to Book	38.29
Revenue Per Employee	$658,963.06
Enterprise Value/EBITDA	N/A

CHWY
Chewy Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CHWY News

CHWY Chewy Inc